For instance, the presence of EGFR mutations in cfDNA represents a milestone for the introduction of the LB in clinical practice, guiding the use of tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) patients when tissue is not available [17,18,19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.